International evidence-based recommendations for polycystic ovary syndrome in adolescents.
Level 1 - systematic review of randomized trials
Evidence-based clinical guideline based on systematic reviews and meta-analyses across 55 prioritized clinical questions evaluated via GRADE.
PubMed 40069730 · doi:10.1186/s12916-025-03901-w
What was done
The authors synthesized evidence for adolescent-specific polycystic ovary syndrome (PCOS) recommendations within the 2023 International Evidence-Based Guideline. Applying AGREE-II criteria, five databases (OVID MEDLINE, All EBM, PsycInfo, EMBASE, CINAHL) were searched through August 2022 for 55 prioritized clinical questions. Multidisciplinary healthcare professionals and consumers evaluated the synthesized evidence using the GRADE framework to assess quality, feasibility, acceptability, cost, and recommendation strength.
What was found
The abstract reports no numerical effect sizes or quantitative outcome statistics. Diagnostic criteria for adolescents require both irregular menstrual cycles (defined by time postmenarche) and clinical or biochemical hyperandrogenism after excluding mimicking conditions. Pelvic ultrasonography (polycystic ovarian morphology) and anti-Müllerian hormone testing are explicitly excluded from diagnostic criteria in this population. Adolescents presenting with only one feature are classified as "at risk." Management recommendations include shared decision-making, healthy lifestyle planning, mental health and metabolic screening, low-dose combined oral contraceptive pills for cycle irregularity and hyperandrogenism, and metformin for metabolic features and cycle regulation.
Why it matters
The guideline defines adolescent-specific diagnostic criteria that intentionally diverge from adult criteria by omitting ultrasound and anti-Müllerian hormone, helping clinicians avoid misdiagnosis while guiding appropriate symptom management.
Limits
The abstract does not report the total number of synthesized studies, patient sample sizes, or quantitative risk estimates. The authors state that direct evidence in adolescents with PCOS remains sparse, leaving all recommendations supported only by low- to moderate-certainty evidence.